Abstract
Purpose: Several studies have reported a positive impact for taxanes in adjuvant breast cancer (BC) treatment in terms of reduced recurrence and mortality. However the impact of the magnitude on overall survival (OS) remains partially controversial. Methods: We examined the impact of taxane-containing adjuvant therapy for patients with early BC on OS, based on the number of deaths and on the calculated number of patients who need to be treated with taxanes to avoid one death (NNT). We classified patients in three different groups according to whether taxanes were administered concurrently or sequentially, and whether all treatment arms had the same or different duration. Results: 1) Taxanes in combination therapy: 8258 patients (4373 with taxanes and 3885 without taxanes), with 723 OS events. Overall survival for taxane-treated patients was 92.7% versus 89.6% for patients not receiving taxanes. NNT was 33. 2) Sequential treatment of unequal duration in the treatment arms: 14,228 patients (7970 with taxanes and 6256 without). Overall survival in taxane-treated patients was 86% compared with 83.2% for patients not receiving taxanes. NNT was 44. 3) Sequential treatment and similar duration in treatment arms: 9511 women (5093 with taxanes and 4418 without). Overall survival in patients treated with taxanes was 87% versus 85% in patients not receiving taxanes. NNT was 50. When the results of all these trials were considered together, the NNT stands at 43 patients. Conclusion: Taxanes afford a modest increase in overall survival in BC patients regardless of how they are given. Translational trials may well help to improve patient selection in the future.
Highlights
Several metanalyses [1,2] have reported a positive impact for taxanes in adjuvant breast cancer treatment in terms of reduced recurrence rates and mortality
We have examined the impact of taxane-containing adjuvant therapy for patients with early breast cancer on overall survival, based on the number of deaths occurring in the different treatment arms and on the calculated number of patients who need to be treated with taxanes to avoid one death (NNT)
There was a greater gain from taxanes in patients with hormone-receptor negative tumours [4,7,14,15,16], than in receptor positive cancers
Summary
Several metanalyses [1,2] have reported a positive impact for taxanes in adjuvant breast cancer treatment in terms of reduced recurrence rates and mortality. Only in a few of these studies [3,6,7,11] there were higher overall survival, while the impact of the magnitude on overall survival remains partially controversial. This information calls for a re-appraisal of the issue of which patient sub-groups really benefit from the addition of taxanes in adjuvant breast cancer therapy
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
